Aditxt invests $1.5M in Evofem via convertible note and warrant as part of merger extension

Aditxt, Inc.

Aditxt purchased a $2,307,692 senior subordinated convertible note of Evofem and a warrant for 149,850,150 shares of Evofem common stock for $1,500,000.
$750,000 of the purchase price was funded on April 8, 2025; remaining $750,000 due by April 16, 2025 under a waiver agreement.
Note bears 8% interest (12% on default), matures April 8, 2028, convertible at $0.0154 per share; warrant exercise price also $0.0154, five-year term.
Evofem waived its termination right under the merger agreement until April 16, 2025; end date extended to September 30, 2025.
Transaction is part of Amendment No. 5 to the Amended and Restated Merger Agreement between Aditxt, Adifem, and Evofem.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.